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Summary ZD9331 is a novel, potent thymidylate synthase (TS) inhibitor which does not require polyglutamation by folylpolyglutamate
synthetase (FPGS) for its activity. In contrast to Tomudex (ZD1694), ZD9331 may therefore be active against tumours with low FPGS activity.
ZD9331 shows anti-tumour activity by both 24-h infusion and bolus administration in the murine thymidine kinase-deficient (TK-/-) lymphoma
L5178Y. In view of the history of renal toxicity with some earlier TS inhibitors and the possible therapeutic use of bolus ZD9331, we have
examined the effects of bolus ZD9331 dose and route of administration on plasma and kidney pharmacokinetics and renal function in mice.
Renal function was assessed by measuring [14C]inulin clearance, and drug concentrations were assayed by reverse-phase high-performance
liquid chromatography (HPLC). Renal function was unaffected by ZD9331 up to 150 mg kg-1 either i.v. or i.p. However, at 200 mg kg-',
glomerular filtration rate was significantly inhibited following i.v. but not i.p. administration. Pharmacokinetic studies showed that these effects
were consistent with the markedly higher plasma drug concentrations occurring during early times following i.v. dosing, although the plasma
drug profiles were otherwise similar for both routes. Kidney drug concentrations were slightly elevated in iv.- versus i.p.-treated animals at the
low dose (50 mg kg-'), with a correspondingly larger area under the curve. However, at the highest dose (200 mg kg-'), peak kidney drug
concentrations were 20-fold higher following i.v. administration than after i.p., with marked kidney retention, resulting in a 50-fold greater kidney
drug exposure for the i.v. versus the i.p. route. These data show that ZD9331 is non-nephrotoxic at active anti-tumour doses (50 mg kg-' i.p.) in
mice, and only at very high bolus i.v. doses is there impaired renal function as a result of very high peak plasma concentrations. These adverse
effects can be readily overcome by i.p. administration, indicating the likely need for short infusions in clinical settings.
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The development of anti-tumour drugs that inhibit thymidylate
synthase initially led to the synthesis of CB3717, which was
shown to have clinical anti-tumour activity but unacceptable
nephrotoxicity (Calvert et al, 1986; Vest et al, 1988). Early studies
established that nephrotoxicity may be a result of poor aqueous
solubility of 2-amino compounds such as CB3717, and it was
shown that 2-desamino CB3717 was more water soluble and less
nephrotoxic (Jones et al, 1989; 1996). A synthetic programme
established that 2-desamino-2-methyl CB3717 (IC1198583) was
non-nephrotoxic and a more potent cytotoxic agent in vitro than
CB3717 (Harrap et al, 1989). Subsequently, the quinazoline TS
inhibitor Tomudex (ZD1694) was developed as a non-nephrotoxic
compound with clinical anti-tumour activity (Clarke et al, 1993;
Jackman et al, 1996). Tomudex can be administered by 15-min
infusion and shows anti-tumour activity in clinical studies
(Jackman et al, 1995a, 1996). ZD1694 is rapidly transported into
cells via the reduced folate carrier (RFC) and requires polygluta-
mation by folylpolyglutamate synthetase (FPGS) to form more
potent penta-polyglutamated TS inhibitors (Jackman et al, 1991;
Gibson et al, 1993). These polyglutamate forms also exibit intra-
cellular retention, which may contribute to toxicity as well as anti-
tumour activity.
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The possibility that intrinsic or acquired resistance to ZD1694
might occur in tumours expressing low levels of FPGS (Jackman
et al, 1995b) has led to the development of more potent, water-
soluble, non-polyglutamatable TS inhibitors (Jackman et al,
1997). Such compounds might be expected to show activity in a
different spectrum of tumours from ZD1694 and to have a more
manageable toxicity profile because of the lack of retained cyto-
toxic metabolites. ZD9331 ((2S)-2-{O-fluoro-p-(N-(2,7-dimethyl-
4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino}
benzamido}-4-(tetrazol-5-yl)butyric acid, Figure 1, molecular
weight 533) represents the lead compound in this novel class ofTS
inhibitors and shows anti-tumour activity by 24-h s.c. infusion (3
mg kg-') as well as bolus administration (50 mg kg-1) in the
murine L5178Y (TK-/-) tumour (Stephens et al, 1994; Jackman et
al, 1997). In view ofthe possible therapeutic use ofbolus ZD9331
and the history ofrenal toxicity with some TS inhibitors, we have
examined the effects of ZD9331 dose and route of administration
on renal function in mice.
MATERIALS AND METHODS
Drug administration and animals
The compound ZD9331 (Figure 1) was provided as a white
crystalline salt. ['4C]inulin was provided as a carboxylic acid
(Amersham, UK, 250 ,uCi in 5 ml, specific activity 6.6 mCi mmol-')
and diluted to an activity of5 ,uCi ml-' in phosphate-buffered saline
(PBS). ZD9331 was dissolved in 0.05 M sodium bicarbonate,
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Figure 1 The chemical structure of ZD9331
adjusted to pH 9.0 and administered eitheri.v. viathe tail vein ori.p.
at 0.01 ml g-' mouse body weight. [14C]inulin was administered at
0.05 gCi g-' (i.e. 0.01 ml g-') i.v. via the tail vein.
Adult female DBA-2 mice were obtained from OLAC (Bicester,
UK) and used at 8-12 weeks of age at a body weight of 15-25 g.
Mice were housed in cages containing untreated sawdust and
allowed access to food and water ad libitum.
Sample preparation
Plasma and tissue samples were prepared using standard tech-
niques (Walton et al, 1996). Briefly, whole blood was obtained
by cardiac puncture into heparinized syringes from halothane-
anaesthetized mice. Plasma was prepared by centrifugation at
12 000 r.p.m. x 2 min in a bench-top microcentrifuge. Kidney and
livertissues were rapidly removed, washed and snap frozen on dry
ice. Frozen plasma and tissues were stored at -20°C for up to 4
weeks prior to analysis.
Individual samples were thawed on ice and handled rapidly.
ZD9331 was extracted from whole plasma or tissue homogenates
(33% w/v in 0.1 M Tris, pH 10.0) by the addition of an equal
volume of acetonitrile, mixing and centrifugation and the super-
natant removed for injection into the HPLC system. Samples were
diluted with Tris buffer (0.1 M, pH 10.0) on to the linear part ofthe
calibration curve prior to HPLC analysis. Extraction efficiencies
were >95%.
HPLC analysis
Concentrations of ZD9331 were measured in biological samples
using reversed phase HPLC on equipment supplied by Kontron
(Watford, UK). Separations were carried out using stainless-steel
columns heated at 45°C and packed with C18 Supelcosil ODS
(10 cm x 4.6 mm, 5 ,um bead size, Sigma, Dorset) and protected
with NewGuard C18 columns (Anachem, Luton, UK). Gradient
elution was carried out from 20-45% acetonitrile in 3 mM tetra-
butyl ammonium hydroxide (pH 6.8) over 15 min and drugs were
detected by UV absorbance at 300 nm on a variable-wavelength
UV detector (Shimadzu, Japan). Peak identity was confirmed by
co-elution with authentic standards and UV absorbance character-
istics. Data acquisition and drug quantification was by peak area
integration using a Kontron MT2 data module. Standard curves
were linear over the range 1-500gM and the lower limit of detec-
tion was 0.3 gM for an injection volume of 20gl representing an
on-column limit of 10 ng. Day-to-day coefficients of variation
were 4.9%.
Glomerular filtration rate measurements
Renal function was assessed in normal DBA-2 mice and in mice
4 or 24 h after different doses of ZD9331 either i.p. or i.v.
by measuring glomerular filtration rate (GFR) as previously
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Figure 2 Effects of ZD9331 dose and route of administration on GFR
measured in DBA-2 mice (A) 4 and (B) 24 h following drug administration.
CB3717 was administered at 150 mg kg-1 i.v. (*) and i.p (K) as a positive
nephrotoxic control. ZD9331 was either administered i.v. (A) or i.p. (A). GFR
was determined by ['4C]-inulin clearance as described in Materials and
methods. Each point represents the mean ±SD (n = 5). Statistics: *P < 0.05,
**P< 0.01 and ***P < 0.001
described (Jodrell et al, 1991a). Briefly, [14C]inulin i.v. pharmaco-
kinetics were determined over a 1-h elimination period to establish
the volume ofdistribution of [14C]inulin, and hence clearance, i.e.
GFR, in normal mice. Drug-treated mice were administered
0.05 ,uCi g-1 ['4C]inulin 4 or 24 h following drug treatment and
[14C]inulin plasma concentrations determined 60 min following
radiotracer administration, a time point shown to be in the elimina-
tion phase of [14C]inulin clearance (Jodrell et al, 1991a). The GFR
in individual animals was calculated and treatment group results
were compared with untreated controls. Significant differences
were determined using Student's t-test.
Pharmacokinetics
Pharmacokinetic parameters were derived using standard proce-
dures (Wagner, 1975; Gibaldi, 1984, and PCnonlin4 manual). [14C]-
inulin clearance kinetics were analysed using a one-compartment
model as previously described (Jodrell et al, 1991a). ZD9331
kinetics were initially fitted to various compartmental models, but
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Table 1 Effects of dose and route of administration on the plasma pharmacokinetics of ZD9331 in DBA-2 mice
Dose Route T... C. t AUC 8 h Clearance
(pg g-1) (min) (min) (ml g-' h-')
(pg ml-,) (pM) (mg ml-' min-') (pM h)
50 i.v. 1 696 1310 57 3.23 75.3 23.3
(605-756) (1140-1420) (2.56-4.03) (59.1-98.9)
50 i.p. 10 74.1 139 93.4 2.60 90.1 34.6
(37-118) (69.4-221) (0.88-3.67) (29.9-91.9)
100 i.v. 1 708 1320 91.7 5.67 109 19.3
(497-1051) (932-1970) (4.73-6.93) (82.7-142)
200 i.v. 1 1939 3635 64.5 19.8 332 16.7
(992-4315) (1860-8100) (14.3-25.9) (260-403)
200 i.p. 10 483 906 99 12.5 315 25.2
(359-608) (673-1140) (9.21-15.6) (241-393)
Data were derived from one or two independent experiments with three mice per time point and 6-9 time points. Half-lives were derived using non-
compartmental pharmacokinetics as described in Materials and methods. Values are mean with range in brackets.
the data and number ofcompartments exhibited by this compound
were unclear. In order to overcome such limitations, and to facili-
tate translation of these data into a clinical setting, kinetics were
analysed using non-compartmental methods (Gibaldi, 1984).
['4C]inulin kinetic data were obtained using non-linear regression
analysis (Jennrich and Sampson, 1968) with a weighting factor of
lI(y+')2, where Y is the estimated value of y. This clearance was
treated as monoexponential (C = Ae-a'), allowing the peak plasma
concentration at t = 0 to be determined (A) and the apparent elimi-
nation rate (a). The volume of distribution (V) was calculated
using the relationship A = dose/V, and ['4C]inulin clearance (CI =
GFR) and hence GFR from CI = Va. Clearance for individual
animals was calculated from CI = V [loge (COIC,)t], where
t = 60 min and CO and C, are [14C]inulin concentration at t = 0 and
60 min respectively.
Non-compartmental parameters were derived using Pcnonlin4
software (Scientific Consulting, Cary, NC, USA) for either i.v.
bolus or non-intravenous drug administration as appropriate.
Briefly, Tmax is the time of maximum observed drug concentration
and Cmax the concentration at that time. The plasma and tissue area
under the curve from time 0 to t(AUC1,) was estimated using the
trapezoidal rule.
Histology
Kidneys and liver from drug-treated and control animals were
removed and fixed in modified Methcarn (60% methanol, 30%
chloroform and 10% glacial acetic acid), prior to sectioning,
staining (haematoxylin and eosin) and histological review. The last
carried out without prior knowledge ofthe treatment details.
RESULTS
Effects of bolus ZD9331 on renal function
The plasma clearance of ['4C]inulin in DBA-2 mice was very
similar to previous values (Jodrell et al, 1991a) being 19.5 and
21.3 ml min-' kg-' in two independent experiments. Figure 2A
shows that there were minimal effects on renal function at
50 mg kg-' ZD9331 (an active anti-tumour dose in the mouse
L5 178Y TK-/- tumour) 4 h after administration. At the interme-
diate dose of 150 mg kg-', there was a suggestion of route-depen-
dent renal effects, with a slight decrease in GFR following i.v. but
not i.p. administration. At the highest dose (200 mg kg-'), this
difference was exaggerated, with a profound decrease in GFR with
the i.v. but not i.p. route.
When renal function was assessed 24 h after drug administra-
tion (Figure 2B) the trend seen at 4 h with the highest dose was
maintained, but GFR inhibition was less profound, suggesting that
recovery of renal function had occurred in the intervening 20 h
period.
The known nephrotoxic TS inhibitor CB3717 (Jodrell et al,
199la) was included as a positive control at 150 mg kg-'. Figure 2
shows that 150 mg kg-' CB3717 i.v. and i.p. inhibited GFR signif-
icantly 24 h after administration and 4 h after i.v. dosing, whereas
ZD9331 had no effect under similar conditions.
Effects of dose and route of administration on ZD9331
distribution in mice
A series of pharmacokinetic experiments were undertaken to
determine if the renal effects described above were due to peak
plasma drug concentrations or non-linear kinetics. In addition,
kidney drug exposures were measured to determine if there was a
correlation with impaired renal clearance.
Plasma kinetics
Plasma drug pharmacokinetics are summarized in Table 1 and
Figure 3A-C. Following 50 mg kg-' i.v., ZD9331 reached a peak
plasma concentration of 696 ,ug ml-' (1.3 mM) and was eliminated
with an apparent terminal elimination t12 of 57.7 min. The clear-
ance was 0.924 ml g-I h-' and the AUC,,8h was 3.23 mg ml-' min
(101 gM h-'). Figure 3 shows that i.p. plasma kinetics were
comparable to i.v. at 50 mg kg-'. However, peak plasma concentra-
tions occurred later (Omin) and were markedly lower (11%)
following i.p. administration (Table 1). The AUC 8 h was slightly
lower (Table 1). Plasma drug concentrations at 4 h were
0.56 gg ml-' (1.1 jIM) and 0.54 jg ml-' (1.0gM) for i.v. and i.p.
routes respectively. The i.p. bioavailability was high at 80%.
At the highest dose of 200 mg kg-' i.v., there were very high
peak plasma levels (1939 jg ml-', 3.5 mm) at the earliest recorded
time point. The AUC i8h was 19.8 mg ml-' min (618 gM h). Once
again, there were much lower peak plasma concentrations
(25%) following i.p. administration, with comparable plasma
kinetics throughout the rest of the time course (Figure 3B).
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In order to determine if there was a route-specific, dose-depen-
dent effect on pharmacokinetics, plasma kinetics were determined
at 100 mg kg-' i.v. and the resulting AUC values for the various
doses and routes are presented in Table 1 and Figure 3C. These
data suggest that over the range 0-200 mg kg-' i.p. drug exposures
are linearly related to dose. However, following i.v. administration
there is a marked deviation from linearity at the highest dose, and
this may be partially responsible for the renal effects seen at this
dose.
Kidney drug distribution
The effects of drug dose and route of administration on kidney
drug levels were also examined, and the data are summarized in
Figure 4 and Table 2. Following i.v. administration of ZD9331 at
50 mg kg-1 (Figure 4A), peak kidney drug concentrations of
163 ,ug g-I (305 gM) occurred at 10 min. The AUC, 8 h was
7.69 mg g-' min (240gM h). Kidney-plasma ratios were initially
low at 35% but rapidly increased to 1000% at 30 min and reached
an equilibrium at 2 h of 200-300%. Following i.p. dosing peak
drug levels were 80% lower with a 50% lower AUC 8 h compared
with the i.v route. Kidney-plasma ratios following i.p. administra-
tion were initially similar to i.v. values and reached a similar
steady-state value of 100-300%.
Following i.v. bolus administration at 200 mg kg-' (Figure 4B),
peak kidney drug levels were delayed compared with lower doses
(CUC 30 versus 10 min) but nearly 12-fold higher at 1929 jg g-'
(3.62 mM). The corresponding AUCQ 0 h was 309 mg g-' min
(9.66 mM h). Initial kidney-plasma ratios were 100% (measured at
5 min) and increased steadily thereafter to plateau values of40 000-
60 000%, i.e. 400-600-fold greaterthan forplasma. By contrast, i.p.
drug administration resulted in markedly lower peak drug levels
(5% ofthe i.v. value) and anAUC,08hofonly 1.8% ofthatforthe i.v.
route. Initial kidney-plasma ratios were only 23%, and these
increased steadily to 1000-2000%, giving ratios 2-3 times higher
than the lower doses of 50 mg kg-'. Steady-state, pseudo-equilibria
were notreached foreither route at the high dose.
Histology
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Figure 5 shows representative samples from kidney sections of
,4 mice following ZD9331 treatment. Figure SA shows a section
from an untreated mouse kidney with normal histology. Four hours
after, high-dose ZD9331 (200 mgkg-') i.v., there was evidence of
tubular dilatation (Figure SB), with the presence of fine granular
casts in the tubules (Figure SC). At the same dose i.p., there was
similar tubular dilatation but no evidence ofcasts, which were also
absent from samples oftissues taken at other doses and time points
200 250 (not shown). Lower drug doses produced some tubular dilatation,
but this did not significantly affect GFR (see Figure 2).
Figure 3 Pharmacokinetics of ZD9331 in DBA-2 mice following
(A) 50 mg kg-' and (B) 200 mg kg-1. Drug was administered either i.v. (0)
or i.p. (0). Data are means ± SD (n = 3-6) determined in two independent
experiments. (C) Effects of dose and route of administration on plasma
ZD9331 kinetics. Error bars represent range (n = 3)
However, i.p. AUC ,8 h was only 63% ofthat following i.v. admin-
istration. Drug concentrations in plasma at 4 h were 0.692 jig ml'
(1.3 jM) and 0.991 jg ml' (1.86 jM) for i.v. and i.p. administra-
tion respectively.
DISCUSSION
ZD9331 was shown to be remarkably non-nephrotoxic following
bolus administration. There was no evidence ofcompromised renal
function (GFR) following doses of up to 150 mg kg-' either i.v. or
i.p. at 4 or 24 h p'ost treatment. This was in marked contrast to
CB3717, a known nephrotoxic TS inhibitor that showed significant
renal toxicity at 150 mg kg-' i.v. at 4 h as well as i.v. and i.p. at 24 h
(Jodrell et al, 1991a). However, at ZD9331 doses of 200 mg kg-'
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Table 2 Effects of dose and route of administration on the pharmacokinetics and distribution of ZD9331 in kidney from DBA-2 mice
Dose Route T7ax C. AUC 8 h
(ig g-1) (min)
(pg g_1) (AM) (mg g-' min-') (gM h)
50 i.v. 10 163 305 7.69 240
(129-238) (242-446) (4.94-11.0) (154-345)
50 i.p. 10 31.5 59.1 1.52 47.5
(26.9-37.5) (50.4-70.3) (1.11-18.8) (34.6-586)
200 i.v. 30 1929 3620 309 9660
(1866-2561) (3500-4810) (222-465) (6920-14500)
200 i.p. 30 96.4 181 5.74 179
(74.6-150) (140-281) (4.22-7.88) (132-246)
Data were derived from one or two independent experiments with three mice per time point and 7 time points. Pharmacokinetics were derived using non-
compartmental pharmacokinetics as described in Materials and methods. Values are mean with range in brackets.
there was an indication of a route-dependent effect on GFR. These
effects were minimal following i.p. administration, but inhibition of
GFR occurred at 24 h and was particularly marked at 4 h following
i.v. administration.
A series of experiments to determine the effects of route of
administration on drug pharmacokinetics, and particularly plasma
and kidney drug distribution, were carried out. These studies
revealed that at low doses (50 mg kg-') peak plasma concentra-
tions were slightly higher for the i.v. versus the i.p. route, with a
correspondingly higher AUC, although the post-peak elimination
time courses were very similar. Consequently, total plasma drug
exposures (AUC) were similar and linearly related to dose up to
100 mg kg-' i.v. However, at 200 mg kg-' there was a marked devi-
ation from linearity for the i.v. but not the i.p. route, which may
relate to the very high peak plasma concentrations (20-fold higher)
that occur after i.v. administration but not during the slower i.p.
absorption phase. This resulted in a marked (50-fold) increase in
AUC0 8 h compared with the i.p. route. Once again, post-peak
plasma elimination kinetics were similar for both routes.
The kinetics of ZD9331 in mouse plasma were similar to those
for the dipeptide TS inhibitor CB30900 (Walton et al, 1996).
Plasma drug concentrations were similar following 100 mg kg-'
i.v., giving a peak value of 456 tg ml-' (716gM) versus
478 ,ug ml-' (898 tM) for ZD9331 at 2 min. Consequently, clear-
ance values and AUCs were also similar. Tomudex, on the other
hand, appears to have slightly lower plasma drug concentrations
following. 100 mg kg-' i.v., with a peak of 162 gg ml-' (342 tM)
at 5 min compared with 411 .tg ml-' (771 ,tM) for ZD9331.
Consequently, Tomudex clearance was correspondingly slower
and the AUC less than for ZD9331 (Jodrell et al, 1991).
Kidney-plasma ratios in mice administered 50 mg kg-' ZD9331
i.p. reached 100% after I h and a steady-state equilibrium of
200-400% at 4 h, a measure of distribution between plasma and
kidney tissue. Steady-state kidney-plasma ratios were similar
following i.v. dosing, but equilibrium was achieved more rapidly
(30 min). At the highest dose, i.p. kidney-plasma ratios did not
reach steady-state pseudo-equilibrium and increased steadily over
the whole time course from an initial value of 20% to 2 000% at
8 h. In those animals administered high-dose ZD9331 i.v. (a
nephrotoxic treatment), there were markedly higher kidney-
plasma ratios throughout the time course and, once again, these
never reached a steady state but increased from 100% at the
earliest time to 100 000% after 8 h, indicating marked drug reten-
tion at a level of around 1 mg g-' (1.87 mM) in kidney tissue.
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Figure 4 Effects of dose and route of administration on ZD9331
kidney-plasma ratios in DBA-2 mice. Drug was administered as a bolus at
(A) 50 mg kg-' or (B) 200 mg kg-' either i.v. (@) or i.p. (0). Corresponding
plasma data and methodology as for Figure 2
Although drug was retained in kidneys from animals administered
drug i.p., this value was only 4-5 ,tg g-' (8-10 gM) and did not
significantly impair renal function, possibly because of the large
functional reserve capacity ofthis tissue.
Histological examination ofkidney tissue following 200 mg kg-'
i.v. together with immunohistochemical staining for ZD9331 (data
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Figure 5 Effects of ZD9331 (200 mg kg-' i.v.) on renal histology from DBA-2
mice. Panel (A) (x 100 H & E) control untreated kidney, (B) (x 100 H & E)
kidney sections from animals treated 4 h previously with 200 mg kg-' ZD9331
i.v. and showing tubular dilitation, and (C) (x 200 H & E) kidney sections from
the same animals as in (B) showing tubular casts
not shown) indicated uniform drug distribution in tissue with no
evidence of drug precipitation. Although there was evidence of
kidney dilatation at both high and low doses, this did not correlate
with impaired renal function or route of administration (Figure 2).
It therefore seems that both total drug exposure and, more particu-
larly, peak plasma drug concentrations contribute to impaired renal
clearance of ZD9331 at very high doses. The observation that
kidney-plasma ratios are > 100% at the earliest time point follow-
ing i.v. dosing and increase thereafter suggests that the critical
events have occurred prior to this time. This clearly implicates peak
plasma concentrations in the acute renal effects of ZD9331. A
reasonable hypothesis is that the very high initial plasma drug
concentrations cause marked kidney drug uptake. These concentra-
tions may exceed the drug's solubility in urine, which is slightly
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acidic (aqueous solubility 100 gM at pH 5.3 and 8 mM at pH 7.4),
causing drug precipitation in this tissue followed by grossly
impaired drug clearance and increased kidney drug exposure
through drug retention. This would eventually lead to impaired
renal function and nephrotoxicity, as for CB3717 (Newell et al,
1986; Jodrell et al, 1991a). However, it is worth noting that these
effects were only seen at very high bolus i.v. doses, which are
unlikely to be employed clinically. Currently, ZD9331 is under-
going phase I clinical investigation employing a 30 min short infu-
sion with starting doses of 0.4 mg m-2 or as a 5-day continuous
infusion (Ratain et al, 1997; Rees et al, 1997) and have reached
doses of67 and 55 mg m-2 respectively. Peak plasma drug concen-
trations in man after 30 min infusion are <1% of those occurring
after 200 mg kg-' i.v. in mouse, and therefore unlikely to have any
effects on renal function.
In conclusion we have shown that ZD933 1 is non-nephrotoxic
at curative anti-tumour doses in mice. However, at very high doses
of ZD9331 that are substantially greater than active anti-tumour
doses in mice, effects on GFR occur and are route dependent.
These appear to relate to the very high peak plasma concentrations
occurring at high i.v. doses, which result in substantial kidney drug
retention. This is absent following i.p. dosing. These data suggest
that ZD9331 should exhibit clinical anti-tumour activity at non-
nephrotoxic doses and that bolus drug administration should take
the form of a short infusion.
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